The combination of gemcitabine and XCT790 remarkably and synergistically decreased the proliferation of tumor cells in mini-PDX models (Figure 6E), suggesting their combination as a better therapeutic strategy than their monotherapy for ERRα-high PC. This evidence concerns the gene ESRRA and neoplasm.